17 May 2017 - Brexit has serious consequences for drug regulation and pharmacovigilance, but as Nigel Hawkes reports, little thought seems to have gone into limiting the damage.

Many people were surprised when they woke on 24 June 2016 to find the UK had voted to leave the European Union, but few were as shocked as those whose job it is to license drugs and keep track of their adverse effects. 

The vote meant that the EMA would have to relocate from London and that UK pharmacovigilance specialists faced an uncertain future.

Read BMJ feature